34 85

Cited 0 times in

유방암에서 c-erbB2의 과발현이 항암화학요법의 치료성적에 미치는 영향

Other Titles
 Overexpression of c-erbB2 and Its Relationship with Chemotherapy in Breast Cancer 
 구자윤  ;  이희대  ;  정우희 
 Journal of the Korean Cancer Association (대한암학회지), Vol.30(3) : 450-456, 1998 
Journal Title
Journal of the Korean Cancer Association(대한암학회지)
Issue Date
Primary breast cancer ; Adjuvant chemotherapy ; c-erbB2 overexpression
PURPOSE: c-erbB2 encodes 185 kDa oncoprotein with tyrosine kinase activity and has homology to the epidermal growth factor receptor. c-erbB2 proto-oncogene is found to be overexpressed in approximately 20 to 30% of primary breast cancer and has been associated with poor prognosis and lower response to conventional chemotherapy.
MATERIALS AND METHODS: We perfonned a study on 40 infiltrating ductal breast cancers treated with primary surgery and adjuvant chemotherapy. We investigated c-erbB2 expression by immunohistochemistry in paraffin-embedded tissue using polyclonal antipeptide antibody(DAKO). We evaluated the relationships between its expression and the results after over 6 cycles of adjuvant chemotherapy including cyclophosphamide, methotrexate and 5-FU.
RESULTS: The median age at diagnosis was 43 years and the median follow-up time was 47.3 months. Thirteen(32.1%) of 40 patients showed the c-erbB2 overexpression in the external domains of protein. There were no correlations among c-erbB2 amplification and other prognostic factors such as hormonal receptors, histologic grade and tumor size. Estrogen receptor and progesterone receptor showed tendency of inverse correlation with c-erbB2 overexpression but it was not statistically significant(p>0.05). c-erbB2 positive patients showed shorter disease free survival compared to c-erbB2 negative patients in univariate analysis(p<0.05)(Kaplan Meire analysis). The patients without c-erbB2 overexpression seemed to survive longer but had no significant survival benefit(p>0.05).
CONCLUSION: These findings suggest that overexpression of c-erbB2 may be a marker of poor response to adjuvant chemotherapy with CMF regimen and may be an indicator of more aggressive therapy.
Files in This Item:
T199802337.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Jung, Woo Hee(정우희)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.